CHA Biotech said Monday that it has acquired a patent for a stem cell culture medium related to preventing skin aging and regenerating it.
This patent acquisition relates to the use of the technique of making culture medium by differentiating umbilical cord or placenta-derived stem cells into dermal tissue cells.
Compared with existing stem cell cultures, the cultures made by applying the patented technology contains a relatively high proportion of substances such as cytokines, growth factors, and protein components that show excellent effects on skin regeneration and anti-aging.
This culture also showed excellent antioxidant activity and collagen expression, which improves wrinkles, skin elasticity, and pigmentation, while stimulating the formation and regeneration of skin tissues.
CHA Biotech and CHA BIO F&C each own 50 percent of the patent, while the latter company plans to showcase a cosmetic product in spring, which incorporates the patented technology.
“Compared with the conventional method in which the umbilical cord or placenta-derived mesenchymal stem cells were directly used as a culture medium, the patented technology has great significance,” said Yu Ji-min, head of research for the patented culture medium. “We plan to register patents for any substances for skin rejuvenation derived from the culture medium patent.”
The company also anticipates that it will be able to develop a therapeutic material according to the progress of research, Yu said.